Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Alternative methods in vitro for screening of endocrine disruptors

M. Dvořáková, K. Kejlová, H. Bendová, M. Rucki, P. Kohout, A. Vavrouš, D. Jírová,

. 2016 ; 37 (Suppl1) : 123-131.

Language English Country Sweden

Document type Journal Article

OBJECTIVES: The aim of this study was to compare in silico data with results obtained in two alternative in vitro methods; and to investigate the potential endocrine activity of bisphenol A analogues. This article contributes to recent findings and brings up-to-date information on development of EU legislation and in vitro testing methods of endocrine disruption. METHODS: In silico approach based on the OECD QSAR Toolbox was used for prediction of potential ligands of human estrogen receptor α. Estrogen Receptor Transactivation in vitro Assay to Detect Estrogen Receptor Agonists and Antagonists (OECD TG 455/457) using the VM7Luc4E2 (formerly designated BG1Luc4E2) cell line was performed for measurement of transactivation activity of the tested substances. Commercially available yeast-based microplate assay (XenoScreen YES/YAS, Xenometrix, Switzerland) for detection of compounds with estrogenic and androgenic agonistic/antagonistic activity was used as a comparative test to estrogen receptor transactivation assay (OECD TG 455/457) and for screening of the agonistic/antagonistic potential of human estrogen receptor and agonistic/antagonistic activity of tested compounds on human androgen receptor. RESULTS: The study showed good correlation between the two in vitro assays and significant correlation with in silico data. All tested substances were identified as agonists for human estrogen receptor α by methods in silico and in vitro, four substances showed a potentially higher estrogenic activity comparing to bisphenol A, two substances were identified as very weak antagonists of human androgen receptor and one compound showed a potential of agonistic activity to human androgen receptor. CONCLUSIONS: The study contributes to recent findings and brings new in silico and in vitro data of bisphenol A analogues, revealing that these analogous substances should be further tested as they may show similar or higher activity in vivo comparing to bisphenol A, which has been recently legislatively regulated.

000      
00000naa a2200000 a 4500
001      
bmc17023225
003      
CZ-PrNML
005      
20240321093813.0
007      
ta
008      
170720s2016 sw f 000 0|eng||
009      
AR
035    __
$a (PubMed)28263540
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Dvořáková, Markéta, $d 1977 leden 17.- $u Third Faculty of Medicine, Charles University, Prague, Czech Republic. National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic. $7 xx0267267
245    10
$a Alternative methods in vitro for screening of endocrine disruptors / $c M. Dvořáková, K. Kejlová, H. Bendová, M. Rucki, P. Kohout, A. Vavrouš, D. Jírová,
520    9_
$a OBJECTIVES: The aim of this study was to compare in silico data with results obtained in two alternative in vitro methods; and to investigate the potential endocrine activity of bisphenol A analogues. This article contributes to recent findings and brings up-to-date information on development of EU legislation and in vitro testing methods of endocrine disruption. METHODS: In silico approach based on the OECD QSAR Toolbox was used for prediction of potential ligands of human estrogen receptor α. Estrogen Receptor Transactivation in vitro Assay to Detect Estrogen Receptor Agonists and Antagonists (OECD TG 455/457) using the VM7Luc4E2 (formerly designated BG1Luc4E2) cell line was performed for measurement of transactivation activity of the tested substances. Commercially available yeast-based microplate assay (XenoScreen YES/YAS, Xenometrix, Switzerland) for detection of compounds with estrogenic and androgenic agonistic/antagonistic activity was used as a comparative test to estrogen receptor transactivation assay (OECD TG 455/457) and for screening of the agonistic/antagonistic potential of human estrogen receptor and agonistic/antagonistic activity of tested compounds on human androgen receptor. RESULTS: The study showed good correlation between the two in vitro assays and significant correlation with in silico data. All tested substances were identified as agonists for human estrogen receptor α by methods in silico and in vitro, four substances showed a potentially higher estrogenic activity comparing to bisphenol A, two substances were identified as very weak antagonists of human androgen receptor and one compound showed a potential of agonistic activity to human androgen receptor. CONCLUSIONS: The study contributes to recent findings and brings new in silico and in vitro data of bisphenol A analogues, revealing that these analogous substances should be further tested as they may show similar or higher activity in vivo comparing to bisphenol A, which has been recently legislatively regulated.
650    _2
$a benzhydrylové sloučeniny $x metabolismus $7 D001559
650    _2
$a biotest $7 D001681
650    _2
$a buněčné linie $7 D002460
650    _2
$a endokrinní disruptory $x metabolismus $7 D052244
650    _2
$a alfa receptor estrogenů $x agonisté $x antagonisté a inhibitory $x metabolismus $7 D047628
650    _2
$a nesteroidní estrogeny $x metabolismus $7 D004968
650    _2
$a lidé $7 D006801
650    _2
$a fenoly $x metabolismus $7 D010636
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kejlová, Kristina $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
700    1_
$a Bendová, Hana $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
700    1_
$a Rucki, Marian $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
700    1_
$a Kohout, Pavel $u Thomayer's Hospital, Prague, Czech Republic.
700    1_
$a Vavrouš, Adam $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
700    1_
$a Jírová, Dagmar $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
773    0_
$w MED00168352 $t Neuro-endocrinology letters $x 0172-780X $g Roč. 37, Suppl1 (2016), s. 123-131
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28263540 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20240321093807 $b ABA008
999    __
$a ok $b bmc $g 1238906 $s 984138
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 37 $c Suppl1 $d 123-131 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...